DCN Dx buys BioSouthTech to tap Latin American patient samples
What's the deal? DCN DxDealroom has a profile for this one. Try Dealroom → has acquired BioSouthTechDealroom has a profile for this one. Try Dealroom →, a Miami-area human biospecimen provider, to expand its sample bank and patient access for drug and diagnostic research. Announced October 29, 2026, the deal's value and financial terms were not disclosed.
What each side brings: DCN Dx combines an immunoassay contract manufacturer, a diagnostics-focused contract research organisation, and a biospecimen business. BioSouthTech adds banked specimens and a collection network across Latin America, including South America and the Caribbean.
Why it matters: Diagnostic developers need specimens that reflect the populations and disease stages their tests target. BioSouthTech widens DCN Dx's sourcing across oncology, neurology, and autoimmune disease research, including treatment-naive patients.
What changes for customers? DCN Dx customers can now request characterised tissue and matched sets off the shelf, or set up prospective collections to their own protocol. The network reaches patients across a range of ancestries and regions, with new geographies and expanded cohorts planned for early 2027.
Why now? The deal builds on DCN Dx's January 2026 launch of prospective biospecimen collection services, extending its push to pair sample access with clinical research and diagnostics development.
In their words: "You can't develop a test for everyone on data from a few," said Jim Boushell, senior vice president of biospecimens at DCN Dx. "Patient diversity must be part of the evidence."
The signal: The acquisition points to a capability expansion rather than a large, quantified transaction — a bet that broader, more diverse specimen access will matter as liquid biopsy assays, including multi-cancer early detection and measurable residual disease tests, move toward patients they were not originally built to serve.
Read more: prnewswire.com
Image credit: DCN Dx, via PR Newswire